Last reviewed · How we verify

NCT06008678

Study of the Resvent RXiBreeze™ PAP System to Treat Obstructive Sleep Apnea

Completed NA Last updated 2 December 2024
What this trial tests

NA trial testing RXiBreeze PAP System, Model RXiBreeze 20A in Obstructive Sleep Apnea in 146 participants. Completed in 29 November 2023.

Timeline
22 August 2023
Primary endpoint
22 November 2023
29 November 2023

Quick facts

Lead sponsorResvent Holding USA LTD
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment146
Start date22 August 2023
Primary completion22 November 2023
Estimated completion29 November 2023
Sites9 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Resvent Holding USA LTD

Who can join

22 and older, any sex, with Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to test the automatic positive airway pressure (APAP) function of the RXiBreeze PAP System in adult subjects with obstructive sleep apnea (OSA). The main questions the study aims to answer are: 1. Is apnea-hypopnea index (AHI) detection using the RXiBreeze PAP System equivalent to apnea-hypopnea index (AHI) detection using PSG? 2. What is the responder rate using the RXiBreeze PAP System? Participants will use the APAP function of the RXiBreeze PAP System while undergoing polysomnography (PSG) for two separate nights in a sleep center. During each visit, participants will also complete two patient reported outcome questionnaires: * Epworth Sleepiness Score (ESS); and * Functional Outcomes of Sleep Questionnaire (FOSQ) short form.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06008678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing